Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 7352 participants.

Also called NCT02545049

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 7,352 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02545049
  • EudraCT 2015-000950-39
Other papers using this trial's data
  • Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes The New England journal of medicine, 2021-12-09 DOI, PubMed 34449181
  • Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial Circulation, 2022-02-08 DOI, PubMed 34775784, PMC8812430 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, Ireland, Israel, Italy, Japan, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02545049. Randomized; quadruple masking; primary purpose treatment. Start 2015-09-17 (actual); primary completion 2021-02-02 (actual). Results posted on 2022-04-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Acronym
FIGARO-DKD
Condition
Diabetic Kidney Disease
Intervention (Drug)
Finerenone (BAY94-8862)
Intervention (Drug)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02545049
Content hash
0ebcba67f32e7a9f972508935d83247de655e4b01d41d5b8fc07ba1aa549c018